自願公告 完成全國首例脈絡膜惡性黑色素瘤質子治療 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院於2025年7月11日，成功完成 全國首例脈絡膜惡性黑色素瘤質子治療。 脈絡膜惡性黑色素瘤是一種常見眼內惡性腫瘤，傳統標準治療方案是眼球摘除 術，這雖然能夠有效控制局部病灶，但不可避免地造成患者的永久性失明和面部 外觀改變，仍有威脅生命的風險。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事王雷先生、宋清寶先生及施波濤先生；及(iii)獨立非執行董事李雪梅女 士、孫延生先生及吳國賢先生。 廣州泰和腫瘤醫 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 茲提述美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公司， 「本集團」）日期為2025年4月25日的截至2024年12月31日止年度之年度報告（「年 報」）。除文義另有所指外，本公告所用詞彙與年報所界定者具有相同涵義。 除年報所載資料外，本公司謹此進一步提供以下有關質子治療服務的補充資料。 質子治療服務為本公司具有高增長潛力的核心業務，有望與本公司其他業務產生 協同效應。為盡快開展質子治療服務，本公司及時調整了其他醫療服務業務的運 營策略，並優化了廣州醫院的成本結構，包括： 1 (1) 本公司關閉或縮減了廣州醫院的部分虧損業務，並減少人員配置。廣州醫院 的僱員人數由截至2023年12月31日的295人減少至截至2024年12月31日的 252人。該調整直接影響了廣州醫院的服務能力，導致2024年廣州醫院接收 和治療的患者 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公 司，「本集團」）自願作出。茲提述本公司日期為2024年7月31日有關終止投票委託 安排的公告（「該公告」）。除另有說明外，本公告所用詞彙與該公告所界定者具有 相同涵義。 於2025年6月24日，本公司獲上海信荷（持有本公司13,333,332股內資股股份）通 知，其於2025年6月24日召開的合夥人會議審議並批准，為了進一步優化上海信 荷的經營決策方式，上海醫學之星將不再為上海信荷的有限合夥人，且楊博士最 終控制的上海信複企業管理中心（有限合夥）將不再為上海信荷的普通合夥人。變 更後上海信荷的各合夥人均獨立於楊博士及其控制的實體及彼等的關連人士（定 義見上市規則）。 因此，上海信荷將不再是本公司控股股東（定義見上市規則）的成員。於本公告 日期，楊博士及其控制的實體，包括Morgancreek Investment Holdings ...

美中嘉和公告，控股股东北京泰和诚于2025年6月20日通过大宗交易出售3280万股公司H股，每股价格 为6.12港元，占公司已发行股份总数的约4.46%。董事会预计此次减持不会对公司的业务经营造成不利 影响。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 內幕消息 本公司控股股東減持股份 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公 司，「本集團」））根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市 規則」）第13.09條以及根據證券及期貨條例（香港法例第571章）第XIVA部所訂明 的內幕消息條文（定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）獲本公司控股股東（定義見香港聯合交易所有 限公司證券上市規則）之一北京泰和誠醫療技術有限公司（「北京泰和誠」）告知， 北京泰和誠於2025年6月20日通過大宗交易出售合共32,800,000股本公司H股，每 股價格為6.12港元，佔本公司於本公告日期已發行股份總數的約4.46%（「出 ...

Summary of Proton and Heavy Ion Therapy Industry Conference Call Industry Overview - The National Health Commission has relaxed licensing for proton and heavy ion therapy, benefiting private hospitals [2][3] - Approximately 53 licenses for proton and heavy ion therapy have been issued in China, but the number of operational centers remains low compared to Europe and the US [3][7] - The latest policy allows non-public hospitals to apply for licenses, which is favorable for private hospitals [3] Key Company Insights - Guangzhou Taikang Cancer Hospital's proton center has been operational since late 2024, treating nearly 200 patients with a single treatment costing 295,000 RMB [2][4] - The hospital's outpatient volume is close to 1,000 visits, indicating strong initial performance [4] - Revenue from proton and heavy ion therapy is approximately 60 million RMB year-to-date, but actual financial income may vary due to settlement cycles with self-pay and commercial insurance patients [5][11] - Shanghai Taihe Cancer Hospital is expected to open in 2026, with its proton center operational by 2027-2028, involving a total investment of 3 billion RMB [8] Financial Performance - The overall revenue of Guangzhou Taikang Cancer Hospital is stable compared to the previous year, with further data on other services pending [6] - The hospital aims to treat 1,000 patients in 2025, which could significantly reduce losses, although net profit may still be challenging to achieve due to high initial investments [10] Market Dynamics - The treatment is not covered by health insurance, with commercial insurance accounting for about 10%-20% of payments, which is expected to increase in the future [11] - The competitive landscape in Shanghai is robust, with the first proton center operating at full capacity, treating around 1,000 patients annually [7] Technological Developments - The company has developed an AI model for proton therapy, currently deployed in Guangzhou, with plans to expand its application to other treatment areas [14][15] - The trend in radiation therapy is moving towards more precise methods, with proton and heavy ion therapies being among the most advanced [12] Future Outlook - The company is focused on optimizing operations in its three hospitals before exploring external growth opportunities [17] - The proportion of revenue from radiation therapy exceeds 50%, highlighting its significance in the company's overall business model [18] - Pricing for proton therapy is expected to remain stable in the short term due to limited competition, but may adjust in the long term as more centers open [19] Regulatory and Competitive Landscape - The company is monitoring the impact of national healthcare price reforms on future gross margins, particularly in the context of service price reductions [13] - Domestic manufacturers are gradually improving their technology, with potential for local production to reduce treatment costs [19]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告不會於美國或其境內直接或間接分發。本公告並不構成或組成於美國購買或認購證券之 任何要約或招攬之一部分。本公告所述之本公司股份並未亦將不會根據1933年美國證券法（經 修訂）（「證券法」）登記，且除非已根據證券法之登記規定登記或獲豁免登記，否則將不得於美 國提呈發售或出售。本公司股份將不會於美國公開發售。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453) 完成根據一般授權配售新股份 獨家整體協調人、配售代理及資本市場中介人 茲提述美中嘉和醫學技術發展集團股份有限公司（「本公司」）日期為2025年5月29 日的公告，內容有關根據一般授權配售18,600,000股新H股（「配售公告」）。除另 有所指外，本公告所用詞 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) 公司名稱： 美中嘉和醫學技術發展集團股份有限公司 呈交日期： 2025年6月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | ...

Company Overview - Meizhong Jiahe Medical Technology Development Group Co., Ltd. is a leading comprehensive oncology medical solution platform in China, focusing on advanced oncology diagnosis and treatment technology research, development, transformation, and application [4] - The company has attracted significant strategic investments from well-known institutions such as CICC Capital, CITIC Xingye, and Shenshan Asset, positioning itself as a mixed-ownership enterprise to promote the development and transformation of medical services in China [4] - Meizhong Jiahe operates multiple international oncology specialty medical institutions across major cities in China, ranking second among private oncology medical groups in terms of the number of owned medical institutions [4] Financial Performance - As of December 31, 2024, Meizhong Jiahe reported total operating revenue of 388 million yuan, a year-on-year decrease of 27.91%, and a net profit attributable to shareholders of -443 million yuan, a year-on-year decrease of 18.8% [2] - The company's gross margin stands at -17.32%, with a debt-to-asset ratio of 67.82% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Meizhong Jiahe's stock [3] - The company's price-to-earnings (P/E) ratio is -9.38, ranking 76th in the healthcare equipment and services industry, which has an average P/E ratio of -20.22 [3] Business Model and Services - Meizhong Jiahe provides comprehensive oncology medical services, including diagnosis and treatment solutions, operational management, equipment leasing, and maintenance services [4] - The company has developed a cloud-based business model to empower enterprise clients, particularly in lower-tier cities, through remote consultation, quality control, supply chain management, and joint research [4][5] - The company has launched platforms such as "Jiahe Cloud Imaging Remote Medical Information Diagnosis Platform" and "Jiahe Feiyun Intelligent Radiotherapy Cloud Platform" to enhance the quality of oncology diagnosis and treatment in underserved areas [4] Technological Advancements - Meizhong Jiahe has strong technical capabilities in radiation therapy, having hosted the first guideline project approved by the National Cancer Center's Radiation Quality Control Expert Committee led by a private medical institution [5] - The company has received approval for additional guidelines related to radiation therapy data auditing and remote treatment planning, further solidifying its expertise in the field [5]

Group 1: Market Overview - The report indicates that the US court's ruling against imposing comprehensive tariffs has led to market optimism regarding the end of the trade war, resulting in a rise in US stock markets and a halt to the five-day decline in A-shares [2][3] - The Hang Seng Index opened lower but rebounded significantly, closing up 315 points or 1.4%, with notable increases in major blue-chip stocks such as Meituan, Alibaba, and JD.com [3] Group 2: Macroeconomic and Industry Dynamics - The Financial Secretary of Hong Kong, Paul Chan, expressed intentions to strengthen ties with the Middle East market, highlighting the potential for collaboration in various financial products, including bonds and derivatives, following the listing of the first Saudi Islamic bond ETF in Hong Kong [6] - The CEO of Hong Kong Exchanges and Clearing, Charles Li, noted the growing momentum for connectivity between Hong Kong and Middle Eastern markets, with significant cooperation already established across various sectors [7] Group 3: Company News - New World Development is in the process of securing an HKD 87.5 billion refinancing deal, which has garnered significant attention from Hong Kong bankers, with at least 12 banks agreeing to terms so far [10] - CSPC Pharmaceutical Group reported a year-on-year decrease of 8.36% in net profit for the first quarter, with total revenue down 21.91%, primarily due to the impact of government policies on drug pricing [11] - Meizhong Pharmaceutical announced a placement of 18.6 million new H-shares at a discount of 19.7% to raise HKD 100 million for various operational needs [12]